c-MET Related In Vivo Models

c-Met is a receptor tyrosine kinase, a/k/a hepatocyte growth factor receptor (HGFR). As a type of proto-oncogene, c-Met overexpression, amplification or gene mutation can promote the development of multiple cancer types, including gastric, liver, lung, breast, pancreatic cancer, and glioblastoma (through the stimulation of multiple signaling pathways).  As a result, c-Met is considered a clinically important therapeutic target.

We offer an extensive panel of c-Met related in vivo models to support project teams.

  • Platform of 14 CDX models with MET overexpression or amplification, covering gastric cancer, liver cancer, glioblastoma, lung cancer and pancreatic cancer
  • Established PDX models with MET overexpression or amplification covering gastric cancer, lung cancer, and liver cancer
  • Additional PDX models include 3 lung cancer models carrying the MET exon 14 skipping mutation
  • Our platform also includes a clinical acquired capmatinib-resistant LU-01-0751 lung cancer PDX model

Check out our comprehensive platform of tumor models and drug-resistant models

c-Met in vivo models-OncoWuXi Newsletter


← Return to Resources

Related Content

What if a constructed PROTAC with a confirmed high-affinity warhead doesn't work as expected? That means we need to take...


Fragment-based drug discovery (FBDD) is one of the most well-developed approaches for projects starting from small, low-affinity compounds.  At the...

← View all Lead Optimization Resources
× peptide, amino acid

Contact An Expert Today!